Ectodysplasin A2 Receptor Antikörper

Produktnummer ABIN6990649

Produktdetails anti-Ectodysplasin A2 Receptor Antikörper

Target: Ectodysplasin A2 Receptor (EDA2R)

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Ectodysplasin A2 Receptor Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Aufreinigung: XEDAR Antibody is affinity chromatography purified via peptide column.

Immunogen: XEDAR antibody was raised against recombinant human XEDAR.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: XEDAR antibody can be used for the detection of XEDAR by Western blot at 0.5 - 2 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 10 μ,g/mL.

Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: XEDAR Antibody is supplied in PBS containing 0.02 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,4 °C

Informationen zur Lagerung: XEDAR antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Details zu Ectodysplasin A2 Receptor

Target: Ectodysplasin A2 Receptor (EDA2R)

Andere Bezeichnung: XEDAR (EDA2R Produkte)

Synonyme: EDA-A2R antikoerper, EDAA2R antikoerper, TNFRSF27 antikoerper, XEDAR antikoerper, 9430060M22Rik antikoerper, Xedar antikoerper, RGD1564025 antikoerper, ectodysplasin A2 receptor antikoerper, EDA2R antikoerper, Eda2r antikoerper

Hintergrund: XEDAR Antibody: X-linked ectodysplasin-A2 receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplatin-A2 (EDA-A2). Two predominantly expressed isoforms, XEDAR-s and XEDAR-L, differ by only a 21-amino region at the juxtamembrane region of the cytoplasmic domain. Neither isoform possesses a death domain and both have been shown to act mainly through TRAF3 and TRAF6 to activate the NF-κ,B and JNK pathways. Cells transfected with XEDAR and treated with EDA-A2 cause the assembly of a secondary complex containing FADD, caspase-8 and caspase-10, leading to the activation caspase-8 and caspase-3, and finally apoptosis. The EDA-A2-induced apoptosis is dependent on caspase-9 activation, as various pharmacological and genetic inhibitors of caspase-8 blocked apoptosis following EDA-A2 treatment.

Gen-ID: 60401

UniProt: Q9HAV5